Repurposing an Osteoporosis Drug for β Cell Regeneration in Diabetic Patients.
Level V
Where this comes from
- Record sourced from PubMed, PMID 26094892.
- Also identified by DOI 10.1016/j.cmet.2015.05.024.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Replenishing the lost or dysfunctional insulin-producing β cell mass in diabetic patients could slow down or reverse disease progression. Kondegowda et al. (2015) now show that osteoprotegerin and denosumab, inhibitors of the receptor activator of the NF-κB Ligand (RANKL) pathway and osteoclast activation, stimulate human β cell proliferation and therefore possess therapeutic potential.
Medical subject headings
- Bone Density Conservation Agents
- Cell Proliferation
- Denosumab
- Insulin-Secreting Cells
- NF-kappa B
- Osteoprotegerin